Charles Ferte

Title: Charles Ferte: Innovator in Radiomics-Based Cancer Monitoring

Introduction

Charles Ferte is an accomplished inventor based in Bethesda, MD (US). He has made significant contributions to the field of cancer research through his innovative work in radiomics. His focus on developing tools that enhance the understanding of tumor-lymphocyte interactions has the potential to improve patient outcomes in cancer treatment.

Latest Patents

Ferte holds a patent for a radiomics-based imaging tool designed to monitor tumor-lymphocyte infiltration and outcomes in cancer patients treated with anti-PD-1/PD-L1 therapies. This invention proposes a biomarker that detects the presence and density of tumor-infiltrating CD8 T-cells in solid tumors without the need for biopsies. Additionally, it aims to assess the immune phenotype of solid tumors and prognose the survival and treatment efficiency of patients undergoing immunotherapy.

Career Highlights

Throughout his career, Charles Ferte has worked with prestigious institutions, including the Institut National de la Santé et de la Recherche Médicale and Université Paris-Saclay. His work has been instrumental in advancing the understanding of cancer immunology and the development of non-invasive diagnostic tools.

Collaborations

Ferte has collaborated with notable professionals in the field, including Elaine Johanna Limkin and Roger Sun. These partnerships have further enriched his research and contributed to the advancement of cancer treatment methodologies.

Conclusion

Charles Ferte's innovative contributions to cancer research through his radiomics-based imaging tool exemplify the potential of technology in improving patient care. His work continues to pave the way for advancements in cancer diagnostics and treatment strategies.